Infrared therapy noncovered
This article was originally published in The Gray Sheet
Executive Summary
More than 4,000 comments from patients and clinicians supporting market-leading Anodyne infrared therapy could not sway CMS to reverse its proposed noncoverage decision for its use to treat peripheral sensory neuropathy, wounds, skin ulcers and related symptoms (1"The Gray Sheet" Feb. 6, 2006, p. 5). CMS' final national coverage decision, released Oct. 24, cites lack of evidence of the treatment's durability, poor methodology in studies with positive results, significant placebo effect and concerns about adverse events reported to FDA...